Personnel Moves Archives - Page 9 of 42

Implantable CGM maker Glucotrack names new VP of marketing

New Glucotrack VP of Marketing Drinda Benjamin. [Image from Drinda Benjamin on LinkedIn]Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing.

Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device.

Benjamin brings more than 20 years of experience in life sciences to Glucotrack, with focus on commercializing health technology. She has past experiences in product development, strategic marketing and more in the diabetes space. That includes work with blood glucose monitoring, CGM, insulin delivery and closed-loop systems.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom appoints a new board director

New Dexcom board director Rimma Driscoll. [Image from Zoetis]Dexcom (Nasdaq: DXCM) + announced today that it appointed Rimma Driscoll to its board of directors.

The San Diego-based continuous glucose monitor (CGM) maker made Driscoll’s appointment effective on Aug. 24. She currently serves as EVP and head of global strategy, commercial and business development and global biodevices for Zoetis.

At Zoetis, a leading animal health company and a Fortune 500 member, Driscoll oversees the global business strategy. She manages the execution of commercial launch plans, external business development and integration efforts.

Get the full story at our sister site, Drug Delivery Business News.

Exo tabs Kurt Hammond as new chief commercial officer

Exo announced today that it appointed healthcare software veteran Kurt Hammond as its chief commercial officer (CCO).

Hammond, a more than 30-year veteran of healthcare software brand scaling, joins from eMed Digital Healthcare. As chief growth officer there, he oversaw sales, customer success, product management, marketing and partnership development functions.

Before eMed, he led six healthcare startups, including Halo Health and Merge Healthcare, to successful exits. His background includes more than 20 mergers and acquisitions in the healthcare market. After IBM acquired Merge in 2015, Hammond became VP of global imaging sales for IBM Watson Health. He eventually earned a promotion to global VP of partnerships and business development.

Santa Clara, California-based Exo says he now holds responsibility for developing and executing a number of strategies. Those include sales, marketing, partnerships and customer success, driving the commercialization o…

Zimmer Biomet CEO leaves to take over another big medtech

Bryan Hanson will take over 3M’s soon-to-be independent healthcare business. [Image courtesy of 3M]Bryan Hanson has left the corner office of ortho tech giant Zimmer Biomet to become CEO of the soon-to-be-independent healthcare business at 3M, the companies announced today.

Hanson takes over 3M’s healthcare business on Sept. 1.

“I have a deep respect and admiration for what 3M has built in health care — strong brands, quality products, commercial excellence, and customer-driven innovation. I look forward to working with the team to more deeply understand and realize the potential of our business as we accelerate our path forward, and build on a legacy of trusted leadership and medical innovation,” Hanson said in a 3M news release.

Zimmer Biomet is promoting its COO Ivan Tornos to become its new CEO.

“I am grateful for Bryan’s leadership in transforming the company and am now looking forward to leading the team and accele…

Tandem Diabetes Care CCO is set to resign

Tandem Diabetes Care (Nasdaq:TNDM) filed an SEC Form 8-K announcing its chief commercial officer’s intent to resign.

Brian B. Hansen, EVP and CCO, notified the company of his decision to resign on Aug. 17. His resignation goes into effect on Dec. 31, 2023.

In connection with Hansen’s resignation, he and the automated insulin delivery technology maker entered into a separation agreement. Under this agreement, dated Aug. 18, Hansen remains employed until June 28, 2024. However, he will be on administrative leave after the Dec. 31, 2023, effective date.

Get the full story at our sister site, Drug Delivery Business News.

Axonics CFO to retire, successor promoted from within

Dan Dearen. [Image from Axonics]Axonics (Nasdaq:AXNX) announced today that Dan Dearan, president and CFO, is retiring from his position at the neuromodulation company.

Irvine, California-based Axonics tabbed Kari Keese, VP of finance and accounting, to succeed Dearen. Her appointment goes into effect on Oct. 2.

“On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years,” said CEO Raymond W. Cohen.

Cohen added that Dearen “played an instrumental role” in the company’s success and the value created for its shareholders.

“It has been a privilege working alongside the talented, mission-driven team at Axonics,” Dearen added. “I am incredibly proud of the impact the company’s therapies have had on improving the quality of life for tens of thousands of incontinence patients. I will follow Axonics with prid…

Heraeus Medevio appoints new president

Heiko Specht [Image courtesy of Heraeus Medevio]

Heraeus Medevio announced that it appointed Heiko Specht to take over as president of the company from Dr. Peter Reimer.

The appointment went into effect on July 1. Specht has held a number of roles at the contract development manufacturing organization since joining in 2000.

His roles include a number of R&D and business leadership positions. Most recently, as chief commercial leader, he oversaw Heraeus product and portfolio management sales and marketing. That included responsibility for the overall business strategy.

As president, Specth will utilize his experience in strategic leadership, growing market share and continuous improvement at Heraeus.

“Heiko’s experience and success in so many areas of our business gives me every confidence he will lead Heraeus Medevio in continuing to achieve double-digit growth each year,” …

HeartBeam names Deborah Castillo VP of regulatory affairs

HeartBeam (Nasdaq:BEAT) announced today that it appointed Deborah Castillo as its VP of regulatory affairs.

Castillo, an experienced biomedical engineer, brings with her knowledge of the FDA, EU and Health Canada regulations, HeartBeam says. Her experience spans cardiovascular diseases, neuroscience and medical devices that support these functions.

Before joining HeartBeam, Castillo served as director of regulatory affairs for neuromodulation at LivaNova. From 2012 to 2018, she held a number of roles at the FDA including acting branch chief, senior lead reviewer and lead scientific reviewer.

In her role at Santa Clara, California-based HeartBeam, Castillo holds responsibilities for interactions with regulatory agencies worldwide. She also supports the company’s clinical development and commercialization efforts for HeartBeam AIMIGo. That platform technology for ECG monitoring remains under review by the FDA.

Castillo said she looks forward t…

Smith+Nephew CFO to step down, revenue guidance increased

Smith+Nephew CFO Anne-Françoise Nesmes [Image courtesy of S+N]Smith+Nephew (LSE: SN, NYSE: SNN) + said today that it now expects 6–7% revenue growth this year, up from a previous 5–6% growth projection.

The British orthopedic and sports medicine products company also announced that CFO Anne-Françoise Nesmes will step down during the second quarter of 2024 and that the board has initiated an external search for a successor.

Revenue was already up 6.6% year-over-year to nearly $1.3 billion in Q2 2023 and up 5.2% to $2.7 billion in the first half of the year. Trading profit was down 5.5% year-over-year to $417 million during H1, with the trading profit margin down 1.6 percentage points year-over-year to 15.3%.

“I am pleased to report strong first-half revenue growth across our business. The continued outperformance in Sports Medicine and Advanced Wound Management – representing 60% of our business – has co…

Inspire Medical appoints former AppliedVR exec as chief medical officer

New Inspire Medical Chief Medical Officer Dr. Charisse Sparks. [Image from Charisse Sparks on LinkedIn]Inspire Medical Systems announced today that it named Dr. Charisse Sparks as its new chief medical officer (CMO).

Minneapolis-based Inspire made Sparks’ appointment effective on July 27. As CMO, she serves as a member of the sleep apnea treatment maker’s executive leadership teams. Sparks’ responsibilities include leading medical and clinical affairs, reporting to President and CEO Tim Herbert.

The appointment of Sparks comes one week after the company named Carlton Weatherby as its new chief strategy officer.

“We are excited to add Dr. Sparks, a board-certified physician with extensive business and leadership experience, to our executive team,” said Herbert. “Inspire has long partnered with leading ear, nose, and throat surgeons, and sleep physicians, as part of our medical advisory boards. In her role as our chief medical officer,…

BD adds former J&J chief medical officer to its board

Dr. Joanne Waldstreicher. [Image courtesy of BD]BD (NYSE: BDX) + announced that it appointed medtech veteran Dr. Joanne Waldstreicher to its board of directors.

Waldstreicher most recently served as chief medical officer at Johnson & Johnson (NYSE: JNJ) + . She held that position from 2012 until her retirement in 2023. As CMO, she provided strategic and operational leadership with responsibility for safety, epidemiology, regulatory and clinical operations. She also oversaw bioethics and late-stage pipeline programs.

Before taking on that role, she served as CMO for Janssen Pharmaceutical R&D, a J&J division, from 2009 to 2012. Prior to that, Waldstreicher was SVP of global drug development from 2002 to 2009. Over her time at J&J, she held responsibilities for clinical research, biostatistics, regulatory affairs and Asia Pacific R&D and medical affairs.

P…

Medtronic neuromod vet joins miniature brain pacemaker developer Motif Neurotech as CTO

Steven Goetz. [Image courtesy of Motif Neurotech]Minimally invasive bioelectronic maker Motif Neurotech announced today that it named Steven Goetz as its chief technology officer (CTO).

Goetz joins after spending more than 26 years in the Neuromodulation unit at Medtronic. There, he led engineering and innovation initiatives for implantable device therapies for a wide range of diseases.

Houston-based Motif Neurotech develops a miniature brain pacemaker designed to stimulate the brain. The company aims for the device to restore healthy circuit activity and treat mental health disorders.

Inserted during a 20-minute procedure, the pea-sized device goes in the skull, above — and not touching — the brain. It can deliver at-home therapy with minimal side effects compared to drugs or less precise brain stimulation. Motif Neurotech has its lead product under development for treatment-resistant depression.

Goetz’s responsibilities include leading all R&…